How Are Responsibilities of a US Agent for Medical Device Registration in the United States Divided?

Key Summary

Medical device manufacturers entering the U.S. market must designate a US Agent responsible for direct communication with the FDA, receiving emergency notifications, assisting in product recalls or adverse events, and maintaining registration information. However, the US Agent does not assume liability for product quality, design, or clinical performance—these remain with the manufacturer. When delineating responsibilities, companies should clearly define obligations in the authorization agreement: the manufacturer must ensure the product meets FDA requirements, provide complete technical documentation, and keep registration up to date; the US Agent must promptly forward FDA instructions, maintain records, and facilitate communication.

Common Risks and Preparation

Common risks include confusing the US Agent role with that of an importer, failing to sign a written agreement, delaying information updates, or appointing an unqualified US Agent. Companies should pre-determine product classification (e.g., Class II requires 510(k)), prepare labels and instructions for use, verify whether ISO 13485 or MDSAP certificates can be reused, and establish a post-market surveillance system. For multi-country registrations, it is advisable to manage the US Agent responsibilities separately from the CE Representative or local agents in GHWP member states to avoid overlap or gaps.

For Chinese medical device companies, a prudent approach is to first perform product classification and documentation gap assessment, then determine whether existing NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in a target market typically impacts technical files, the US Agent, importer coordination, label language, quality system evidence, and subsequent change maintenance. If the project is initially driven solely by 'which documents to submit,' it may lead to deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends that companies plan the US Agent issue within the framework of GHWP member states and multi-country market access strategies, using a single set of reusable core technical documents to support localization in different markets, rather than creating documents from scratch for each country.

Applicable Scenarios and Core Issues

Non-U.S. medical device manufacturers must designate a US Agent as required by 21 CFR 807.40 before selling products in the United States. The US Agent is not a regulatory agent but bears critical communication duties. Many companies mistakenly believe the US Agent is liable for product safety; in fact, the US Agent's obligations are limited to: receiving FDA notifications to the registrant (e.g., warning letters, 510(k) deficiencies, or recall orders) and acting as a contact point when the FDA cannot directly reach the manufacturer. Therefore, manufacturers must accurately understand the boundaries of the US Agent's responsibilities to avoid incorrectly transferring compliance obligations in the agreement.

The US Agent does not participate in product design, manufacturing, or clinical evaluation, but the manufacturer must authorize the US Agent to take preliminary actions (e.g., initiating a recall) in emergency situations (e.g., when a product causes serious injury). This division is crucial for selecting a US Agent and drafting the agreement. Particularly for companies entering the U.S. market for the first time, the professionalism of the US Agent directly impacts registration efficiency and post-market risk management.

Registration Judgment Logic

• Step 1: Determine if the product is within FDA jurisdiction. If it is a medical device (including in vitro diagnostics), complete Establishment Registration and Device Listing.
• Step 2: Based on product classification (Class I, II, III) and exemption status, decide whether a 510(k) or PMA submission is required.
• Step 3: Identify the applicant entity—the manufacturer is the registrant; the US Agent is only a contact person in the registration information and does not bear legal responsibility for the application documents.
• Step 4: Assess whether existing NMPA, CE, ISO 13485, or MDSAP documentation can support U.S. registration. For example, risk management, clinical evaluation, and performance verification reports may be reused but must be adjusted per FDA guidance (e.g., ISO 14971 combined with 21 CFR 820).
• Step 5: Ensure labels and instructions for use meet FDA format requirements (e.g., symbol usage, UDI requirements).
• Step 6: Designate a US Agent and sign a written agreement. The agreement must include: clear division of responsibilities for FDA communication, notification timelines for information changes (usually within 15 days), record retention requirements, and termination clauses.

For multi-country registration scenarios (e.g., applying for CE, FDA, and GHWP member states simultaneously), companies should avoid confusing the US Agent role with the CE Authorized Representative (EU REP) or local agents in Southeast Asia. The US Agent is not responsible for product registration submissions or certificate control but must maintain registration documents and communication records for at least three years.

Documentation and Evidence

Companies need to prepare the following documents to clarify responsibility division and complete US Agent designation:

• Written authorization agreement: specifying the US Agent's name, address, contact person, scope of authorization, validity period, and termination conditions.
• FDA Establishment Registration confirmation (FEI number) and Device Listing confirmation.
• Communication record templates between the manufacturer and US Agent (e.g., emergency notification procedures).
• US Agent qualification evidence (e.g., professional background, regulatory experience, physical U.S. address).
• Copies of labels and instructions for use (showing manufacturer and US Agent information).
• Technical documentation summary (e.g., 510(k) summary or PMA file list).

Additionally, companies should retain the US Agent's annual compliance confirmation letter and any forwarded FDA official notifications. The evidence chain must allow the FDA to trace clear responsibility division during inspections.

Common Mistakes

• Confusing the US Agent with the importer: The importer handles logistics and customs clearance; the US Agent handles communication.
• Failing to clearly define responsibility boundaries in the authorization agreement (e.g., requiring the US Agent to assume product liability beyond its statutory duties).
• Not updating the US Agent's information (address, contact person changes) in a timely manner, resulting in undelivered FDA notifications.
• Appointing a US Agent without a physical U.S. address or proper qualifications, which FDA considers invalid.
• Treating the US Agent as the sole registration contact, ignoring the manufacturer's own legal responsibilities.
• In multi-country registrations, using the same agent as both the US Agent and CE Representative, causing overlapping duties.

Company Preparation Checklist

• Confirm whether the product is under FDA jurisdiction and determine its classification.
• Prepare technical documentation compliant with FDA requirements (risk management, performance data, clinical evidence).
• Draft an authorization agreement template with responsibility division clauses.
• Select a qualified US Agent (e.g., a professional consulting firm or a U.S.-based company).
• Provide complete company information (name, address, contact person) to the US Agent.
• Establish an internal process for information changes, ensuring notification to the US Agent and FDA within 15 days.
• Retain all registration documents, communication records, and agreement copies for at least three years.
• Periodically verify that the US Agent is still effective and assess its service quality.

AIMEILI's Perspective

The most common misconception is that the US Agent will 'cover' compliance responsibilities. In reality, the US Agent serves only as a communication bridge; the manufacturer remains fully responsible for product design, manufacturing, labeling, post-market surveillance, and all other aspects. In the early stages of a project, companies should prioritize product classification and pathway determination rather than first finding a US Agent. With respect to reusing existing documentation, CE-compliant ISO 14971 risk management reports and clinical evaluation reports (e.g., MEDDEV 2.7.1) can be adapted for FDA requirements, but must be supplemented with U.S.-specific requirements (e.g., UDI, recall regulations). For multi-country registrations, companies should appoint separate agents for each core market to avoid cross-impact if one agent changes. Certificate control (e.g., FDA 510(k) clearance letters, listing numbers) must remain with the manufacturer; the US Agent cannot alter them independently. For changes and renewals (e.g., company name change, ownership change), the US Agent's role is to assist in notifying the FDA, but the manufacturer must proactively track ownership transfers or quality system updates.

Frequently Asked Questions

Q1: Can the US Agent be changed? What is the process?

Yes. The manufacturer must update the US Agent information in the FDA Establishment Registration system and sign a new authorization agreement. It is generally recommended to notify the former US Agent and the new one 30 days before the change to avoid interruption in FDA communications. After the change, the manufacturer should ensure the former US Agent transfers all relevant records (if any) and update labels and listing information.

Q2: Does the US Agent need special qualifications or certifications?

The FDA does not require the US Agent to hold a specific certificate. However, the US Agent must meet the following conditions: (1) have a physical address in the United States (not a P.O. Box); (2) be available during FDA business hours; (3) be familiar with FDA regulations and communication procedures. Many companies choose professional regulatory consulting firms as their US Agent because they can provide more efficient communication support.

Q3: What is the difference in responsibilities between a US Agent and an importer?

The US Agent is a statutory communication contact designated by the FDA, responsible for forwarding official notifications and assisting with emergency events, but not involved in the physical movement of products. The importer is responsible for clearing goods through customs, paying duties, and ensuring the products comply with FDA import requirements (e.g., device listing). The two roles can be different entities, but the manufacturer must ensure coordination between them to avoid information silos.

Q4: If the US Agent breaches the agreement, what consequences does the manufacturer face?

Breach by the US Agent (e.g., failure to timely notify the FDA of a warning letter) may cause the manufacturer to miss response deadlines, potentially leading to product detention, automatic deregistration, or administrative penalties. Liability typically falls on the manufacturer, as the manufacturer has the duty to select a competent agent. Therefore, the agreement should clearly specify the US Agent's liability for damages caused by its negligence.

Implementation Guidance

In practice, companies should break this issue into five tasks: regulatory determination, documentation preparation, evidence reuse, localization, and post-market maintenance, rather than having a single department compile documents ad hoc. This approach helps identify documentation gaps early and aligns sales, R&D, quality, and regulatory teams on target country requirements.

If a company plans to enter multiple markets simultaneously, it is advisable to first create a unified core technical document set, then supplement with country-specific authorization, labeling, language, forms, and local agent documentation. The efficiency of multi-country registration often depends on whether the initial documentation framework is unified, not on the speed of submission for a single country.

• First, confirm whether the product falls under the medical device regulatory scope of the target country.
• Then, determine the risk class, registration pathway, and applicant entity.
• Verify that the technical documentation, quality system, and clinical evidence are mutually supportive.
• Clarify local agents, authorized representatives, and certificate control.
• Establish post-market change, renewal, and vigilance event maintenance mechanisms.